Black Box Warning

What a Boxed Warning Means

A boxed warning, often called a black box warning, prominently identifies serious risk information at the beginning of prescribing information. FDA describes this section as containing contraindications or warnings about serious adverse reactions that may lead to death or serious injury. It does not replace the rest of the label. (FDA labeling guide, Table C)

Evidence basis: High for the cited regulatory description and documented label contents. This is not a grade of a medicine’s safety or effectiveness.

Read the Exact Product Label

The relevant information includes the product and formulation, the warning’s subject, the evidence described and any product-specific contraindications. Highlights summarize important information and refer readers to the full prescribing information. (FDA labeling guide)

A warning for one formulation should not be assigned to another product solely because they share an ingredient or drug class. The two exenatide labels below illustrate why that distinction matters.

GLP-1 Example: Byetta and Bydureon BCISE

U.S. product	Label revision checked	Thyroid C-cell tumor boxed warning
Byetta, exenatide injection	September 2025	No boxed warning in this label
Bydureon BCISE, exenatide extended-release injection	May 2025	Boxed warning present

Sources: Byetta prescribing information and Bydureon BCISE prescribing information, accessed September 29, 2026. This is a comparison of two label features, not a complete list of GLP-1 products or a ranking of their overall safety.

Bydureon BCISE’s boxed warning describes thyroid C-cell tumors in rats and says the human relevance is unknown. It lists a personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 as contraindications. Those statements belong to this specific label and should not be converted into generic prescribing instructions for an entire class. (Bydureon BCISE, boxed warning and section 5.1)

What the Human-Evidence Wording Does Not Establish

“Unknown” does not mean that human risk has been proved absent or that its frequency has been measured precisely. The Bydureon BCISE label discusses reported medullary thyroid carcinoma cases with another GLP-1 medicine and says those reports cannot establish or exclude causality. This entry therefore does not provide a numerical human thyroid-cancer risk estimate. (Bydureon BCISE, section 5.1)

Likewise, spontaneous adverse-event reports cannot by themselves establish an event rate. FDA describes this limitation for its AEMS reporting data. (FDA AEMS dashboard)

Frequently Asked Questions

Does a product without a boxed warning have no serious risks?

No. Other label sections can describe important risks. Byetta, for example, includes warnings and precautions even though it has no boxed warning. (Byetta, section 5)

Is a boxed warning the same as the entire safety profile?

No. The wider safety profile also includes adverse-reaction data, contraindications, interactions and information about particular populations. (FDA labeling guide)

Does this glossary decide whether a medicine is suitable for me?

No. This is an explanation of labeling, not an individual treatment assessment. Questions about a medicine or a change to treatment belong with a qualified healthcare professional.

Educational information only. This entry is not medical advice.

Sources

1. FDA: Frequently Asked Questions about Labeling for Prescription Medicines, especially Table C.
2. Byetta prescribing information, revised September 2025, hosted by NLM DailyMed.
3. Bydureon BCISE prescribing information, revised May 2025, hosted by NLM DailyMed.
4. FDA: AEMS Public Dashboard and data limitations.

Sources checked September 29, 2026. This entry describes U.S. labeling and does not substitute another jurisdiction’s requirements.